Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Cut to Hold at Wall Street Zen

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

Other analysts have also issued reports about the stock. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Wells Fargo & Company upped their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Finally, Canaccord Genuity Group initiated coverage on Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They issued a “buy” rating and a $62.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.29.

Kiniksa Pharmaceuticals International Trading Down 0.6%

Shares of NASDAQ KNSA opened at $45.78 on Friday. Kiniksa Pharmaceuticals International has a 12 month low of $18.25 and a 12 month high of $49.12. The firm has a market capitalization of $3.50 billion, a PE ratio of 61.86 and a beta of 0.06. The firm has a fifty day simple moving average of $43.83 and a two-hundred day simple moving average of $40.67.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, February 24th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The company had revenue of $202.13 million during the quarter, compared to analysts’ expectations of $200.86 million. During the same period in the prior year, the business posted ($0.12) earnings per share. The company’s revenue for the quarter was up 65.0% on a year-over-year basis. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

Insider Activity

In other news, COO Eben Tessari sold 12,048 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the sale, the chief operating officer directly owned 16,666 shares of the company’s stock, valued at $692,638.96. The trade was a 41.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Barry D. Quart sold 20,129 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.51, for a total value of $835,554.79. Following the completion of the sale, the director owned 12,546 shares in the company, valued at $520,784.46. The trade was a 61.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 80,782 shares of company stock worth $3,458,916. Insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently modified their holdings of KNSA. Mark Sheptoff Financial Planning LLC raised its position in shares of Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock worth $674,000 after purchasing an additional 250 shares during the last quarter. Mariner LLC grew its position in Kiniksa Pharmaceuticals International by 2.0% during the 4th quarter. Mariner LLC now owns 13,519 shares of the company’s stock valued at $558,000 after purchasing an additional 266 shares during the last quarter. Virtus Investment Advisers LLC grew its position in Kiniksa Pharmaceuticals International by 2.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock valued at $678,000 after purchasing an additional 406 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its stake in Kiniksa Pharmaceuticals International by 7.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock valued at $317,000 after purchasing an additional 508 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.